IL143012A0 - Pharmaceutical composition comprising an anti-cancer agent and at least one peptide - Google Patents

Pharmaceutical composition comprising an anti-cancer agent and at least one peptide

Info

Publication number
IL143012A0
IL143012A0 IL14301299A IL14301299A IL143012A0 IL 143012 A0 IL143012 A0 IL 143012A0 IL 14301299 A IL14301299 A IL 14301299A IL 14301299 A IL14301299 A IL 14301299A IL 143012 A0 IL143012 A0 IL 143012A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
peptide
cancer agent
agent
cancer
Prior art date
Application number
IL14301299A
Other languages
English (en)
Original Assignee
Synt Em Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt Em Sa filed Critical Synt Em Sa
Publication of IL143012A0 publication Critical patent/IL143012A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14301299A 1998-11-30 1999-11-26 Pharmaceutical composition comprising an anti-cancer agent and at least one peptide IL143012A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815073A FR2786398B1 (fr) 1998-11-30 1998-11-30 Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
PCT/FR1999/002939 WO2000032237A1 (fr) 1998-11-30 1999-11-26 Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide

Publications (1)

Publication Number Publication Date
IL143012A0 true IL143012A0 (en) 2002-04-21

Family

ID=9533369

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14301299A IL143012A0 (en) 1998-11-30 1999-11-26 Pharmaceutical composition comprising an anti-cancer agent and at least one peptide
IL143012A IL143012A (en) 1998-11-30 2001-05-07 Pharmaceutical composition comprising an anti-cancer agent and at least one peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143012A IL143012A (en) 1998-11-30 2001-05-07 Pharmaceutical composition comprising an anti-cancer agent and at least one peptide

Country Status (13)

Country Link
US (1) US7527792B1 (da)
EP (1) EP1135169B1 (da)
JP (1) JP2002538080A (da)
AT (1) ATE232398T1 (da)
AU (1) AU769766B2 (da)
CA (1) CA2352134A1 (da)
DE (1) DE69905392T2 (da)
DK (1) DK1135169T3 (da)
ES (1) ES2192420T3 (da)
FR (1) FR2786398B1 (da)
IL (2) IL143012A0 (da)
PT (1) PT1135169E (da)
WO (1) WO2000032237A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
CA2461575A1 (en) 2001-10-16 2003-04-24 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
EP3217947B1 (en) 2014-11-12 2022-03-09 University of Mississippi Medical Center Kidney-targeted drug delivery systems
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
BR9808863A (pt) * 1997-04-14 2001-09-18 Univ California Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
FR2830016B1 (fr) 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau

Also Published As

Publication number Publication date
DE69905392T2 (de) 2003-10-09
DK1135169T3 (da) 2003-06-10
FR2786398B1 (fr) 2002-12-27
WO2000032237A1 (fr) 2000-06-08
IL143012A (en) 2007-05-15
ES2192420T3 (es) 2003-10-01
EP1135169A1 (fr) 2001-09-26
AU769766B2 (en) 2004-02-05
ATE232398T1 (de) 2003-02-15
EP1135169B1 (fr) 2003-02-12
JP2002538080A (ja) 2002-11-12
PT1135169E (pt) 2003-06-30
US7527792B1 (en) 2009-05-05
CA2352134A1 (fr) 2000-06-08
FR2786398A1 (fr) 2000-06-02
DE69905392D1 (de) 2003-03-20
AU1391100A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
PL313223A1 (en) Nigella sativa as a therapeutic agent
DE69716135D1 (en) In 6-position durch thio substituierte paclitaxele
ZA991885B (en) Novel methods and compositions for delivery of taxanes.
ZA949309B (en) Composition for the production of therapeutic products in vivo
IL128801A (en) Pharmaceutical composition comprising a substance inhibiting no synthase
PL349028A1 (en) Cancer treatment composition and method using natural plant essential oils
ZA991296B (en) Hexametaphosphates as an agent for treating wastes, preparing construction materials and stabilizing soils.
IL143012A0 (en) Pharmaceutical composition comprising an anti-cancer agent and at least one peptide
EP2020237A3 (en) Ceramide and chemotherapeutic agents for inducing cell death
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
WO2003053180A3 (de) Wirkstoffhaltige unterwäsche
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
IL133004A0 (en) Pharmaceutical compositions comprising an aldose inhibitor and an ace inhibitor
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
WO2001034131A3 (en) Combination chemotherapy
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
MY117808A (en) Cancer cell nuclease activator
WO1999021574A3 (en) Enhancement of morphogen activity
ZA200006020B (en) Voacamine as anti-malarial agent and anti-malarial agent containing voacamine.
WO1999047150A3 (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
WO2000040752A3 (en) Cancer associated genes and their products
EP1197228A4 (en) DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
IL139303A0 (en) Treatment of arthritis and other similar conditions
HUP9903098A3 (en) Combination comprising vx478, zidovudine and/or 1592u89 and pharmaceutical composition containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed